About
Cancer Immunotherapy, CAR-T, Bispecific Antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalStem Cell & Cellular TherapyAntibodyChina
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
4
As Collaborator
3
Total Enrollment
547
By Phase
PHASE1/PHASE2: 4PHASE1: 3
By Status
RECRUITING: 5NOT_YET_RECRUITING: 2
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06928363Lead Sponsor
A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors.
PHASE1/PHASE2Not yet recruiting
212 participants
Started: May 1, 2025 · Completed: Dec 15, 2027
NCT06518876Lead Sponsor
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome
PHASE1Not yet recruiting
21 participants
Started: Aug 31, 2024 · Completed: Dec 31, 2027
NCT06445803Collaborator
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
PHASE1Recruiting
48 participants
Started: May 31, 2024 · Completed: Dec 31, 2026
NCT06223646Lead Sponsor
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
PHASE1/PHASE2Recruiting
29 participants
Started: Jan 11, 2024 · Completed: Mar 31, 2026
NCT06175780Lead Sponsor
Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors
PHASE1Recruiting
189 participants
Started: Dec 28, 2022 · Completed: Dec 28, 2025
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...